EIC Accelerator Hopeful Cellbox Labs Puts Gut Microbes on a Chip
Drug developers test new compounds on cells in plastic dishes and on animals, and both are poor stand-ins for a human gut full of bacteria. Cellbox Labs, a Riga company that grew out of the University of Latvia, makes organ-on-chip devices: small plastic chips with two channels separated by a membrane, in which human cells grow under a steady flow of medium. Its next step, according to the project title the EIC published, is to put the gut microbiome on the chip as well.
The European Innovation Council announced on 16 November 2026 that it had selected 35 companies for the EIC Accelerator. SIA Cellboxlab appears on the list of selected companies with MICROVERSE, a "Microbiome-Enabled Organ-on-Chip Platform for Versatile Experimental Research and Scalable Evaluation", recommended for blended finance. The EIC also named it as one of five examples in its announcement, for "microbiome-enabled organ-on-chip technology for advanced research and scalable testing". Selection is not yet a contract: the list states that it "does not constitute a formal commitment for funding", and the EIC expects grant agreements within three months.
Company file
- Legal entity
- SIA Cellboxlab, registration number 42103111196, trading as Cellbox Labs
- Registered
- 19 June 2020, Commercial Register of Latvia
- Address
- Rātsupītes iela 1 k-1, Riga
- Founders
- Gatis Mozoļevskis (CEO), Roberts Rimša (CTO), Artūrs Ābols (CSO)
- Known investors
- Buildit VC, 12 LatBAN angels, ASP Asset Management AIFP
- EIC project
- MICROVERSE, July 2026 cut-off, blended finance; not yet in CORDIS
- Staff
- 15 in the 2025 accounts
Not the other Cellbox
Cellbox Labs is unrelated to Cellbox Solutions GmbH of Hamburg, which makes portable incubators for shipping living cells and holds its own EIC Accelerator project, CELLBOX on CORDIS, from the March 2023 cut-off. At least one start-up database reviewed for this article merges the two.
A chip without tubes
The company's product page describes a "Dynamic Organ Chip" with vertically stacked channels: blood-vessel cells on one side of a permeable membrane, tissue cells such as gut lining on the other. The chips need no external tubing, which the company says cuts leaks and contamination, and they can be imaged under a microscope without being removed. An automated system runs them, and Silicon Canals reported in August 2025 that it scales from 8 to 24 chips through a modular manifold. The company also sells contract research on intestinal, cancer and blood-vessel models, and lists host and microbiota interaction "including strict anaerobes" among its applications.
That last point is what MICROVERSE builds on. Strict anaerobes are bacteria that cannot tolerate oxygen, while the human cells on the other side of the membrane need it. The company's pitch, in the interview published by the Investment and Development Agency of Latvia (LIAA) on 5 November 2025, is that its device is simpler than competing models and needs no specialist knowledge. No benchmark against other commercial chips could be found in the sources reviewed on 17 November 2026.
Some of the science is public. The company's resources page lists three papers. One, in PLOS ONE on 17 June 2025, co-authored by Mozoļevskis and Rimša under University of Latvia affiliations, found that serum-supplemented medium flowing through such chips exerts about ten times the wall shear stress a standard estimate predicts. Another, a 2024 paper in Materials Today Bio by Goluba and colleagues, kept patient-derived pancreatic tumour tissue alive on a chip for more than 50 days and measured tumour markers in the outflow. The third is a protocol for a mucus-producing gut-on-a-chip model.
"We will be able to make the drug development process more efficient, cheaper and more accessible worldwide"
Gatis Mozoļevskis, co-founder, to Invest in Latvia, 12 August 2022From two institutes to a company
The work began in 2019 as a collaboration between the Latvian Biomedical Research and Study Centre and the Institute of Solid State Physics of the University of Latvia, Invest in Latvia reported in 2022. Ābols came from the first, Mozoļevskis and Rimša from the second. After an EIT Health Innostars grant in 2020, the founders set up the company, which the Lursoft register extract shows was registered on 19 June 2020. The same 2022 article says the company acquired patent rights to technology from the Institute of Solid State Physics and had its own patent application pending; no granted patent in the company's name could be found in the sources reviewed on 17 November 2026.
The record
From a 2019 university collaboration to an EIC selection in 2026
The organ-on-chip work began at two University of Latvia institutes in 2019; the company was registered in 2020, made its first sales in 2024 by its own account, and was selected for the EIC Accelerator in November 2026.
- 2019University collaborationResearchers from the Biomedical Research and Study Centre and the Institute of Solid State Physics start the organ-on-chip work
- Jun 2020Company registeredSIA Cellboxlab enters the Latvian Commercial Register on 19 June 2020 after an EIT Health Innostars grant
- 2024First customersResearch institutes and universities in Germany and Estonia, per the company in a LIAA interview
- May 2024Pre-seed roundRound led by Buildit VC with 12 LatBAN angels and ASP Asset Management, as reported by AIN€935K
- May 2025MIRACLE startsERDF project to add oxygen, glucose, pH and barrier sensors to the Cellbox Labs instrument, running to April 2027
- Aug 2025Non-dilutive fundingCompany reports €3.3M, part of it state aid under the Tech4Cure IPCEI€3.3M
- Nov 2026EIC selectionMICROVERSE is among 35 companies selected for the EIC Accelerator, recommended for blended financeSelected
Invest in Latvia, 12 August 2022; Lursoft; AIN, 13 May 2024; LIAA, 5 November 2025; Silicon Canals, 8 August 2025; ISSP UL, MIRACLE project page; EIC, 16 November 2026.
The register shows an active company with no insolvency, liquidation or tax debt recorded as of 10 November 2026, and paid-in capital of €24,340.88 registered on 27 October 2026. Each of its three beneficial owners holds 23.45%. Datreal, which republishes Latvian register data, names them as the three founders and lists ASP Asset Management AIFP with 9.11%.
Mostly public money
The one private round reported in the sources reviewed is a €935,000 pre-seed round, reported by AIN on 13 May 2024, led by Buildit VC with a syndicate of 12 LatBAN angels, ASP Asset Management AIFP and its owner. The money was to finish the first version of the automated device and start sales. Datreal also lists two Buildit funds, GenMedica Baltic and Cellbox Holding among the shareholders, without dates for those stakes.
In August 2025 the company announced €3.3 million in non-dilutive funding, reported by Silicon Canals and by the Institute of Solid State Physics, which calls Cellbox Labs its spin-off. Part of it, both say, is state aid under Tech4Cure, the Important Project of Common European Interest in healthcare. The Commission approved Tech4Cure in July 2025 with up to €403 million of aid notified by France, Hungary, Italy, Slovakia and Slovenia, pharmaphorum reported; that report does not name Latvia or the company, and the split of the €3.3 million is not public.
Two public projects can be checked separately. PERFORM-CHIP, a personalised microbiota research and testing chip platform credited in the company's website footer, is listed by Datreal with €1,335,818 from 23 July 2025 to 31 December 2027. MIRACLE, an ERDF project with the Institute of Solid State Physics, has a total budget of €855,505 and runs from 1 May 2025 to 30 April 2027 to build oxygen, glucose, pH and barrier sensors into the Cellbox Labs instrument. Its quarterly reports for November 2025 to January 2026 mention a response being prepared to a European Patent Office search report.
The money
Public money outweighs the one private round reported
Each bar comes from a different source and the figures may overlap: the €3.3M reported in August 2025 is not broken down, so PERFORM-CHIP may be part of it. MIRACLE's budget is the whole project's, not the company's share. The EIC grant amount for MICROVERSE is not published.
AIN, 13 May 2024; Silicon Canals, 8 August 2025; Datreal summary of public funding records; ISSP UL, MIRACLE project page. Values in € millions.
What the accounts show
The filed annual reports, as summarised by Datreal, show a company still small in revenue. Net turnover was €364,106 in 2023 and fell to €32,650 in 2024, a year with a €447,946 loss and negative equity of €412,272. In 2025 turnover rose to €113,600, the company reported a €465 profit, and equity turned positive at €286,438 on assets of €922,697. The reports do not say how much of the income came from chip sales, research services or grants.
The accounts
Revenue fell in 2024 and recovered only partly in 2025
Net turnover dropped from €364,106 in 2023 to €32,650 in 2024, when the company lost €447,946. In 2025 turnover reached €113,600 and the result was a €465 profit.
Filed annual reports of SIA Cellboxlab as summarised by Datreal, read 17 November 2026. Values in € thousands.
Staff moved with the money: 10 employees in 2023, 6 in 2024 and 15 in 2025. In the LIAA interview the company said it had 14 specialists, that its first customers came in 2024 from research institutes and universities in Germany and Estonia, and that exports could make up as much as 97% of turnover. It named none of those customers. The US company Altis Biosystems lists Cellbox Labs as a research collaborator developing intestinal systems with its RepliGut cells.
The team
Staff more than doubled in 2025
The filed reports show 10 employees in 2023, 6 in 2024 and 15 in 2025. The company told LIAA in November 2025 that it had 14 specialists.
Filed annual reports of SIA Cellboxlab as summarised by Datreal; LIAA, 5 November 2025.
What MICROVERSE promises
Beyond its title, the EIC has published nothing about MICROVERSE. Sources reviewed on 17 November 2026 show no CORDIS project and no EIC Fund portfolio entry for the company, which is expected this soon after the announcement: the EIC says grant agreements follow within three months, and equity is decided separately by the EIC Fund. The grant amount for the company is not published. Across the round, the EIC put proposed grants at €84 million for 35 companies, with 32 to be assessed for equity of up to €10 million each.
The competition
One of 35 companies chosen from 453 full applications
The EIC's November 2026 round narrowed 453 full applications to 88 interviews and 35 selected companies; 32 of them will be assessed for EIC Fund equity.
EIC, announcement of 16 November 2026.
The policy wind is behind the field. On 10 April 2025 the US Food and Drug Administration announced a plan to phase out animal testing requirements for monoclonal antibodies and other drugs, naming "organ-on-a-chip systems that mimic human organs" among the replacements. In Europe the Commission published a roadmap on 1 June 2026 towards phasing out animal testing in chemical safety assessments, covering 15 domains including pharmaceuticals, RAPS reported; the same report says the Commission considers direct replacement not yet feasible for complex endpoints. A European supplier of the chips fits that agenda, but neither policy is a purchase order.
- Selection for the EIC AcceleratorSelectedListed with MICROVERSE for blended finance, EIC, 16 November 2026.
- Signed grant agreementToo earlyExpected within three months of the announcement; no CORDIS project in sources reviewed on 17 November 2026.
- Commercial organ chip and automated systemOn saleOffered on the company website; first customers in 2024 per the LIAA interview, none named.
- Microbiome-enabled chip platformNot yet publicAnaerobe co-culture is listed as a service application; no published validation of a microbiome chip found on 17 November 2026.
- EIC Fund equityToo earlyNo EIC Fund investment announced by the company or the EIC.
What the company says
A simple, tube-free organ-on-chip system that cuts animal testing, sold mostly abroad, now extended to living gut bacteria for drug, food and probiotic testing.
What the record shows
A company registered in 2020 with 15 staff, €113,600 of turnover in 2025, a €935,000 pre-seed round, several public projects, peer-reviewed chip papers and an EIC selection; no named customer and no published microbiome chip yet.
Verdict
Cellbox Labs is further along than many companies in this round: it sells a chip and an instrument, has research customers by its own account, and its staff more than doubled in 2025. It is also small, with turnover of €113,600 and a funding history carried mostly by public programmes. MICROVERSE asks it to solve the hard part of gut modelling, keeping oxygen-shy bacteria next to human cells, and nothing about that work is public yet beyond the EIC's title.
The reporting is based on publicly available sources, listed below.
Sources
- EIC, European Innovation Council selects 35 deep tech companies for its Accelerator support, 16 November 2026
- EIC, list of selected companies, May and July 2026 cut-offs
- Lursoft, SIA Cellboxlab, 42103111196
- Datreal, SIA Cellboxlab, filed accounts and public funding, read 17 November 2026
- Cellbox Labs, products and services, about us and resources
- LIAA, Latvian company Cellboxlab develops a product that accelerates medicine development, 5 November 2025
- Invest in Latvia, Organs-on-a-chip also being developed in Latvia, 12 August 2022
- AIN, Latvian biotech Cellbox Labs raises €935K, 13 May 2024
- Silicon Canals, Cellbox Labs secures €3.3M in funding, 8 August 2025
- Institute of Solid State Physics, University of Latvia, spin-off Cellbox Labs secures more than €3 million, 12 August 2025
- Institute of Solid State Physics, University of Latvia, MIRACLE project page
- pharmaphorum, European Commission approves 2nd IPCEI to sum of €403m, 23 July 2025
- Altis Biosystems, partnerships
- Šints et al., Physical model of serum supplemented medium flow in organ-on-a-chip systems, PLOS ONE, 17 June 2025
- Goluba et al., Personalized PDAC chip with functional endothelial barrier, Materials Today Bio, vol. 29, 2024
- CORDIS, CELLBOX project of Cellbox Solutions GmbH
- FDA, plan to phase out animal testing requirement for monoclonal antibodies and other drugs, 10 April 2025
- RAPS, EU publishes roadmap to reduce reliance on animal testing, 2 June 2026
Industry
HealthLife science tools
- Focus
- Research models
- Laboratory instruments
- Analytical services
- Technologies
- Microfluidics
- Tissue engineering
- Lab automation
- Keywords
- Organ-on-chip
- Gut microbiome
- Animal testing alternatives
- Drug development
- Toxicity testing
- Personalised medicine